



National Prostate Cancer Collaborative

Final Report (August to December 2023)



In August 2023, the American Cancer Society’s National Roundtables and Coalition Business Unit collaborated with leadership and colleagues from the Patient Support Pillar, Discovery (research) Pillar, and ACS CAN to launch the **ACS National Prostate Cancer Collaborative**. The purpose of the Collaborative was to convene a diverse group of national thought leaders and advocates in the field of prostate cancer with intent to: discuss current incidence, mortality, and disparity trends; coalesce around shared priorities addressing common clinical challenges; offer guidance on effective evidence-based or promising practice changes; and ultimately, renew the nations’ collaborative energy to shift our current prostate cancer paradigm.

Utilizing a coalition and consensus building process, participants in the Collaborative engaged in collective dialogue to determine areas to coordinate efforts and accelerate progress in improving prostate cancer outcomes. At the conclusion of this four month process, the Collaborative identified three priority areas, paired challenges with tangible solutions, and agreed to ongoing support and next steps in activating on these consensus-built recommendations.

PROJECT GOALS



Convene a focus group of key thought leaders for action-oriented **dialogue** regarding concerning trends in prostate cancer.



Facilitate strategic discussions to co-create a set of **strategic priorities** to ensure that all men receive care that has been shown to significantly decrease the morbidity and mortality of prostate cancer.



Focus on the **full breadth of the cancer continuum**, including screening, imaging, treatment of localized and advanced disease as well as survivorship.

ACKNOWLEDGING OUR PARTNERS



The ACS National Prostate Cancer Collaborative is an invited group of over 38 individual participants who represent leading cancer advocacy organizations, research institutions, government agencies, professional associations and societies, leading public health organizations, patient advocates, corporate partners, among other relevant industry leaders.

The American Cancer Society graciously thanks the following individuals for their participation, support, and many contributions to this initiative and continued shared endeavors.



Adrian Backus, JD, MDiv
Prostate Health Education Network
(PHEN)

Melissa Buffalo
American Indian Cancer Foundation

Courtney Bugler, CFRE
ZERO Prostate Cancer

Monica Chatwal, MD
Moffitt Cancer Center

Iona Cheng, PhD, MPH
University of California, San Francisco

Peter Choyke, MD
National Cancer Institute

Garfield Clunie, MD, FACOG
NYU Langone Health; National Medical
Association

Chris Collier
Arkansas Prostate Cancer Foundation

Matthew Cotter, PhD
Pfizer Oncology

William Dahut, MD
American Cancer Society

Ruth Etzioni, PhD
Fred Hutch Cancer Center

Thomas Farrington
Prostate Health Education Network
(PHEN)

Ilya Gipp, MD, PhD
GE HealthCare

Kathleen Goss, PhD
American Cancer Society

Ingrid Hall, PhD, MPH
Centers for Disease Control and
Prevention

Lannis Hall, MD, MPH
Siteman Cancer Center, Washington
University School of Medicine

Sushant Hardikar
AstraZeneca

Charlie Hill
Hampton Roads Prostate Health Forum

Arif Kamal, MD, MBA, MHS
American Cancer Society

Kenneth Kami
MDxHealth

Rick Kittles, PhD
Morehouse School of Medicine

Harshad Kulkarni, MD
BAMF Health

Lisa Lacasse, MBA
American Cancer Society Cancer Action
Network (ACS CAN)

Lorelei Mucci, ScD, MPH
American Cancer Society

Merel Nissenberg
National Alliance of State Prostate Cancer
Coalitions (NASPCC)

Yaw Nyame, MD, MS, MBA
University of Washington

William Oh, MD
Prostate Cancer Foundation; Mount Sinai
Health System

Chris Parker, MBBS, MPH
Georgia Health Policy Center

Steve Patierno, PhD
Duke Cancer Institute

Jennifer Phillips
Johnson & Johnson

Wyatt Pickner
American Indian Cancer Foundation

Walter Rayford, PhD, MD, MBA
Consortium on Disparities of Urologic
Conditions (ConDUC)

Sarah Shafir, MPH
American Cancer Society

Kirsten Sloan
American Cancer Society Cancer Action
Network (ACS CAN)

Robert Smith, PhD
American Cancer Society

Tawana Thomas-Johnson
American Cancer Society

Ray Wezik, JD
American Urological Association

Karen Winkfield, MD, PhD
Meharry Vanderbilt Alliance

ACS Team Support:

Molly Black

Kerri Gober

Caleb Levell, MA

Jessie Sanders

Summary of Participation

The ACS National Prostate Cancer Collaborative officially kicked off on August 28th, 2023.


Participants responded to **surveys** to provide insights on challenges and opportunities prior to the first Collaborative meeting. Surveys were also used as a tool between each meeting to further prioritize strategies and actions, advance discussions, and build consensus.

An **in-person Summit** on September 28 brought all Collaborative participants together for a day of facilitated dialogue and resulted in a first draft of recommendations for **three priority areas**.

In the final phases of work, Collaborative participants refined final recommendations and were led through impact and feasibility discussions to highlight strategies and activities primed for immediate **alignment and activation**.

The development of the three priority areas with accompanying priority statements and documented strategies and activities have outlined a **consensus-built roadmap** that when executed will improve prostate cancer outcomes for all men.

Project Outputs




3 Surveys

- August - Initial identification of challenges, gaps, emerging trends, opportunities, and areas for collaboration
- September - Socializing discussion themes and building consensus on identified challenges and areas for collaboration
- October - Rank strategies for feasibility and impact



3 Convenings

- August 28th (virtual) - 2 Hours
- September 28th (in-person, Washington, DC) - Full Day
- November 3 (virtual) - 1.5 Hours



3 Consensus-Built Draft Priority Areas with Identified Strategies and Activities

1. Risk Assessment and Screening
2. Initial Treatment Strategies and Treatment Around Localized Prostate Cancer
3. Addressing Advanced Prostate Cancer with Appropriate Imaging Therapies, and Supports



Risk Assessment and Screening

Improving access to and awareness of recommended prostate cancer screening, risk assessment, and follow-up through community and professional education, with a focus on high-risk men especially Black men, will decrease cancers diagnosed at advanced stage and improve outcomes.

Strategies and Activities:

Strategy 1: Identify and communicate with high-risk groups without stigmatization

- Create a tool (risk assessment quiz- one public/community facing and one for clinicians) to increase awareness of individual risk and importance of screening.
- Create an awareness campaign to drive clinical and community members to the tool (risk assessment quiz) to educate on the importance of screening and preventative/healthy practices.

Strategy 2: Increase primary care understanding and screening of high-risk individuals

- Develop a targeted primary care clinician campaign to educate on current state of science of prostate cancer screening (data, case studies) and populations at highest risk and partner with professional societies to influence and disseminate.

Strategy 3: Increase prostate cancer screening among Black men with approaches coordinated with and accepted by the Black community.

- Invite/partner with Black organizations (national/state/local) and communities including family and women to amplify and expand successful community engagement initiatives to increase prostate cancer screening.



Initial Treatment Strategies and Treatment Around Localized Prostate Cancer

Improving access to early and equitable multidisciplinary treatment strategies will increase likelihood of patients receiving appropriate standard of care, improving outcomes for high-risk patients, while reducing overtreatment and optimizing quality of life.

Strategies and Activities:

Strategy 1: Improve clinical decision support for men newly diagnosed with prostate cancer by using the already existing tools/guidelines

- Empower navigators/CHWs (community health workers) to review materials with patients that guide and inform from diagnosis through treatment.
- Utilize multidisciplinary teams to ensure clinical risk stratification to produce personalized treatment recommendations.

Strategy 2: Leverage tech/AI for telehealth to improve access to care when providers are limited

- Identify successful telehealth in rural settings, document case studies, and learn from them by sharing best practices.
- Develop clinical care nodes and virtual prostate cancer tumor boards to translate multidisciplinary strategies in rural areas.
- Encourage patients at diagnosis to enroll in a prostate cancer care app.

Strategy 3: Ensure patients navigate the system without delay by better coordinating communication between them and multidisciplinary teams

- Study the impact of multidisciplinary teams on the outcomes of prostate cancer.
- Educate the full case team on inclusive language/clarifying language to reduce confusion on treatment options.



Addressing Advanced Prostate Cancer with Appropriate Imaging, Therapies, and Supports

Improving timely and equitable implementation of evidence-based and emerging strategies will produce better survival rates, quality of life, and supportive care for patients with metastatic prostate cancer.

Strategies and Activities:

Strategy 1: Aggregate diverse data sources to understand the treatment patterns and sequences associated with improved outcomes for patients with metastatic prostate cancer

- Partner with organizations including the Commission on Cancer (CoC) to focus a project on mining treatment patterns among metastatic patients.
- Abstract high quality structured data from EMRs to understand metastatic disease outcomes.

Strategy 2: Increase concordance to evidence-based treatment for metastatic prostate cancer, including precision-based approaches such as genomics, imaging, and biomarkers

- Offer every patient germline and somatic testing.
- Incentivize the use of tailored, interactive, culturally relevant and plain language educational tools for patients and clinicians for metastatic prostate cancer.

Strategy 3: Improve supportive care to address social, emotional, and financial needs of patients with metastatic prostate cancer

- Join efforts with the national navigation roundtable to address metastatic prostate cancer.



Launching the National Prostate Cancer Roundtable

The ACS National Prostate Cancer Collaborative clearly demonstrated the interest and energy for working together to impact prostate cancer outcomes. Recognizing a clear need for continued collaborative energy and alignment, the American Cancer Society is dedicated to launching the National Prostate Cancer Roundtable in 2024.


Want to learn more?

Please send questions to Jessie Sanders, Director, National Roundtables and Coalitions (Jessie.Sanders@cancer.org).

Next Steps




Publish findings of the Collaborative



Recruit 50 Organizational Members



Identify leadership, including chairs and steering committee members



Host a formal launch event of the ACS National Prostate Cancer Roundtable



THANKING OUR SPONSORS

Johnson & Johnson

